Vir Biotechnology (VIR)
NASDAQ:VIR

Vir Biotechnology Stock Analysis & Ratings

Vir Biotechnology Stock Analysis Overview

Smart Score
4
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The Vir Biotechnology stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

VIR

VIR Stock Stats

Previous Close$31.26
Open$31.56
Bid0 x 0
Ask0 x 0
Today’s Range$30.6 - $34.06
52-Week Range$29.48 - $83.50
Volume1.17M
Average Volume1.51M
Market Cap$4.45B
Beta-1.54
P/E Ratio-39.3
EPS-0.86
Earnings DateMar 31, 2022

Company Description

Vir Biotechnology

Vir Biotechnology, Inc. engages in the provision of technologies to treat and prevent infectious diseases. Its technology platforms include antibody, T cell, innate immunity, and siRNA. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in 2016 and is headquartered in San Francisco, CA.
Sector
Healthcare
Industry
Biotechnology
CEO
George A. Scangos
Employees
395
Website
www.vir.bio
ISIN
US92764N1028
Address
499 Illinois Street, San Francisco, CA, 94158, US

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

Vir Biotechnology News


VIR FAQ

What was Vir Biotechnology’s price range in the past 12 months?
Vir Biotechnology lowest stock price was $29.48 and its highest was $83.50 in the past 12 months.
    What is Vir Biotechnology’s market cap?
    Vir Biotechnology’s market cap is $4.45B.
      What is Vir Biotechnology’s price target?
      The average price target for Vir Biotechnology is $138.67. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $300.00 ,the lowest forecast is $36.00. The average price target represents 308.21% Increase from the current price of $33.97.
        What do analysts say about Vir Biotechnology?
        Vir Biotechnology’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.
          When is Vir Biotechnology’s upcoming earnings report date?
          Vir Biotechnology’s upcoming earnings report date is Mar 31, 2022 which is in 61 days.
            How were Vir Biotechnology’s earnings last quarter?
            Vir Biotechnology released its earnings results on Nov 04, 2021. The company reported $0.82 earnings per share for the quarter, beating the consensus estimate of -$0.048 by $0.868.
              Is Vir Biotechnology overvalued?
              According to Wall Street analysts Vir Biotechnology’s price is currently Undervalued.
                Does Vir Biotechnology pay dividends?
                Vir Biotechnology does not currently pay dividends.
                What is Vir Biotechnology’s EPS estimate?
                Vir Biotechnology’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Vir Biotechnology have?
                Vir Biotechnology has 130,880,000 shares outstanding.
                  What happened to Vir Biotechnology’s price movement after its last earnings report?
                  Vir Biotechnology reported an EPS of $0.82 in its last earnings report, beating expectations of -$0.048. Following the earnings report the stock price went down -15.054%.
                    Which hedge fund is a major shareholder of Vir Biotechnology?
                    Among the largest hedge funds holding Vir Biotechnology’s share is Oracle Investment Management Inc. It holds Vir Biotechnology’s shares valued at 51M.

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis